Patents by Inventor Juan José Lasarte Sagastibelza
Juan José Lasarte Sagastibelza has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11560407Abstract: The present invention provides peptides of general formula (I) and salts thereof, wherein: R1 and R2, taken together, form a birradical linker; and R2? is hydrogen; or, alternatively, R1 is selected from hydrogen, —C(?O)—CH2—NH—C(?O)—(C1-C5)alkyl, and —C(?O)—(C1-C20)alkyl; one of R2 and R2? is hydrogen and the other is selected from —C(?O)NR3R4, and —C(?O)OH; and R3 and R4 are same or different and are selected from hydrogen and (C1-C10)alkyl. These peptides are highly efficient in binding and inhibiting FoxP3, being efficient in inhibiting and blocking Treg cell functionality, which make them useful in the treatment of cancer. The present invention also provides constructs comprising the peptide of formula (I) as well as combinations comprising the peptide of formula (I), the construct or both.Type: GrantFiled: April 20, 2020Date of Patent: January 24, 2023Assignee: FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADAInventors: Inés Noelia Casares Lagar, Juan José Lasarte Sagastibelza, Teresa Lozano Moreda, Julen Oyarzabal Santamarina, Maria Obdulia Rabal Gracia
-
Publication number: 20200317733Abstract: The present invention provides peptides of general formula (I) and salts thereof, wherein: R1 and R2, taken together, form a birradical linker; and R2? is hydrogen; or, alternatively, R1 is selected from hydrogen, —C(?O)—CH2—NH—C(?O)—(C1-C5)alkyl, and —C(?O)—(C1-C20)alkyl; one of R2 and R2? is hydrogen and the other is selected from —C(?O)NR3R4, and —C(?O)OH; and R3 and R4 are same or different and are selected from hydrogen and (C1-C10)alkyl. These peptides are highly efficient in binding and inhibiting FoxP3, being efficient in inhibiting and blocking Treg cell functionality, which make them useful in the treatment of cancer. The present invention also provides constructs comprising the peptide of formula (I) as well as combinations comprising the peptide of formula (I), the construct or both.Type: ApplicationFiled: April 20, 2020Publication date: October 8, 2020Inventors: Inés Noelia CASARES LAGAR, Juan José LASARTE SAGASTIBELZA, Teresa LOZANO MOREDA, Julen OYARZABAL SANTAMARINA, Maria Obdulia RABAL GRACIA
-
Patent number: 10654896Abstract: The present invention provides peptides of general formula (I) and salts thereof, wherein: R1 and R2, taken together, form a birradical linker; and R2? is hydrogen; or, alternatively, R1 is selected from hydrogen, —C(?O)—CH2—NH—C(?O)—(C1-C5)alkyl, and —C(?O)—(C1-C20)alkyl; one of R2 and R2? is hydrogen and the other is selected from —C(?O)NR3R4, and —C(?O)OH; and R3 and R4 are same or different and are selected from hydrogen and (C1-C10)alkyl. These peptides are highly efficient in binding and inhibiting FoxP3, being efficient in inhibiting and blocking Treg cell functionality, which make them useful in the treatment of cancer. The present invention also provides constructs comprising the peptide of formula (I) as well as combinations comprising the peptide of formula (I), the construct or both.Type: GrantFiled: October 19, 2017Date of Patent: May 19, 2020Assignee: FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADAInventors: Inés Noelia Casares Lagar, Juan José Lasarte Sagastibelza, Teresa Lozano Moreda, Julen Oyarzabal Santamarina, Maria Obdulia Rabal Gracia
-
Publication number: 20190276496Abstract: The present invention provides peptides of general formula (I) and salts thereof, wherein: R1 and R2, taken together, form a birradical linker; and R2? is hydrogen; or, alternatively, R1 is selected from hydrogen, —C(?O)—CH2—NH—C(?O)—(C1-C5)alkyl, and —C(?O)—(C1-C20)alkyl; one of R2 and R2? is hydrogen and the other is selected from —C(?O)NR3R4, and —C(?O)OH; and R3 and R4 are same or different and are selected from hydrogen and (C1-C10)alkyl. These peptides are highly efficient in binding and inhibiting FoxP3, being efficient in inhibiting and blocking Treg cell functionality, which make them useful in the treatment of cancer. The present invention also provides constructs comprising the peptide of formula (I) as well as combinations comprising the peptide of formula (I), the construct or both.Type: ApplicationFiled: October 19, 2017Publication date: September 12, 2019Inventors: Inés Noelia CASARES LAGAR, Juan José LASARTE SAGASTIBELZA, Teresa LOZANO MOREDA, Julen OYARZABAL SANTAMARINA, Maria Obdulia RABAL GRACIA
-
Publication number: 20160215039Abstract: This invention relates to the use of a polypeptide in the production of an immunostimulatory agent, said polypeptide comprising a sequence corresponding to the EDA domain of fibronectin, a fragment of the EDA domain which can bind to TLR4 or a variant of said EDA domain or a fragment which can bind to TLR4 and which has a homology of more than 70% with any form or natural fragment of the EDA domain. The invention also relates to the production methods and applications of said agent.Type: ApplicationFiled: August 26, 2015Publication date: July 28, 2016Inventors: Claude LECLERC, Juan Jose LASARTE SAGASTIBELZA, Marta GORRAIZ AYALA, Jesus PRIETO VALTUENA
-
Patent number: 9155783Abstract: This invention relates to the use of a polypeptide in the production of an immunostimulatory agent, said polypeptide comprising a sequence corresponding to the EDA domain of fibronectin, a fragment of the EDA domain which can bind to TLR4 or a variant of said EDA domain or a fragment which can bind to TLR4 and which has a homology of more than 70% with any form or natural fragment of the EDA domain. The invention also relates to the production methods and applications of said agent.Type: GrantFiled: June 13, 2006Date of Patent: October 13, 2015Assignee: PROYECTO DE BIOMEDICINA CIMA, S.L.Inventors: Claude Leclerc, Juan Jose Lasarte Sagastibelza, Marta Gorraiz Ayala, Jesus Prieto Valtuena
-
Publication number: 20140056943Abstract: The present invention relates to an immuno-stimulant combination for prophylaxis and treatment of hepatitis C, characterised in that it comprises: a TLR3 agonist, a CD40 agonist and the NS3 protein of the hepatitis C virus. Moreover, the invention relates to the pharmaceutical compositions comprising said immuno-stimulant combination, to the use thereof, and to a kit composed of said pharmaceutical compositions. Finally, the present invention relates to a method for producing an immune response to the hepatitis C virus and to a vaccine against said virus.Type: ApplicationFiled: September 27, 2013Publication date: February 27, 2014Applicant: PROYECTO DE BIOMEDICINA CIMA, S.L.Inventors: Aintzane ZABALETA AZPIROZ, Francisco BORRAS CUESTA, Jesus PRIETO VALTUENA, Pablo SAROBE UGARRIZA, Juan Jose LASARTE SAGASTIBELZA
-
Patent number: 8524860Abstract: The invention relates to peptides of general formula (I), wherein X is absent or X is present and is X14 or X14-X15, wherein X14 and X15, independently from one another, represent an amino acid; their functional variants and fragments, and their pharmaceutically acceptable salts, having the capacity to bind to scurfin and inhibit its biological activity, therefore they regulate or block the activity of regulatory T (Treg) lymphocytes. They are applicable in the treatment of infectious and neoplastic diseases.Type: GrantFiled: November 14, 2008Date of Patent: September 3, 2013Assignee: Proyecto de Biomedicina CIMA, S.L.Inventors: Inés Noelia Casares Lagar, Francisco Borrás Cuesta, Pablo Sarobe Ugarriza, Jesús Maria Prieto Valtueña, Juan José Lasarte Sagastibelza
-
Publication number: 20130064790Abstract: The invention relates to peptides having the capacity to bind to interleukin-10 (IL-10) and their use in the treatment of clinical conditions or pathological disorders associated to IL-10 expression, particularly to a high IL-10 expression, for example, infectious diseases, tumors, cancers and acute damage conditions.Type: ApplicationFiled: March 8, 2012Publication date: March 14, 2013Applicant: PROYECTO DE BIOMEDICINA CIMA, S.L.Inventors: Lorea MANTEROLA CAREAGA, Inés Noelia CASARES LAGAR, Nancy Díaz-Valdés Farray, Javier DOTOR DE LAS HERRERÍAS, Juan José LASARTE SAGASTIBELZA, Pablo SAROBE UGARRIZA, Jesús PRIETO VALTUEÑA, Francisco BORRÁS CUESTA
-
Publication number: 20120237535Abstract: The invention relates to immunogenic conjugates comprising an immunogenic region of human papilloma virus E7 protein and the fibronectin EDA region, as well to compositions comprising said conjugates and to dendritic cells obtained by stimulation with said conjugates and compositions. Moreover, the invention relates to methods for the treatment of diseases caused by the human papilloma virus (HPV) using said conjugates, compositions and dendritic cells.Type: ApplicationFiled: September 10, 2010Publication date: September 20, 2012Applicant: PROYECTO DE BIOMEDICINA CIMA, S.L.Inventors: Pedro Berraondo-Lopez, Juan Jose Lasarte Sagastibelza, Christina Mansilla Puerta, Jesus Maria Prieto Valtuena, Pablo Sarobe Ugarriza
-
Patent number: 8148334Abstract: The invention relates to peptides having the capacity to bind to interleukin-10 (IL-10) and their use in the treatment of clinical conditions or pathological disorders associated to IL-10 expression, particularly to a high IL-10 expression, for example, infectious diseases, tumors, cancers and acute damage conditions.Type: GrantFiled: March 27, 2008Date of Patent: April 3, 2012Assignee: Proyecto de Biomedicina Cima, S.L.Inventors: Lorea Manterola Careaga, Inés Noelia Casares Lagar, Nancy Díaz-Valdés Farray, Javier Dotor de las Herrerías, Juan José Lasarte Sagastibelza, Pablo Sarobe Ugarriza, Jesús Prieto Valtueñ, Francisco Borrás Cuesta
-
Publication number: 20110268757Abstract: The invention relates to methods for increasing immunogenicity of an antigenic peptide by means of its covalent coupling to a modulin derived peptide (PSM, phenol soluble modulin). In particular, the binding of PSM?, PSM? and PSM? peptides to an antigen (from a pathogen or a tumor associated protein) increases the capacity of the antigen to activate an immune response in vivo.Type: ApplicationFiled: December 2, 2009Publication date: November 3, 2011Applicants: INSTITUT PASTEUR, PROYECTO DE BIOMEDICINA CIMA, S.L.Inventors: Francisco Borrás Cuesta, Inés Noelia Casares Lagar, María del Carmen Durántez Delgado, Juan José Lasarte Sagastibelza, Claude Leclerc, Jesús María Prieto Valtueña, Pablo Sarobe Ugarriza
-
Publication number: 20110076304Abstract: The invention relates to an adapter protein comprising a coxackievirus and adenovirus receptor (CAR) region and a human CD40 ligand and to the uses thereof for promoting adenoviral transduction of dendritic cells while at the same time promoting maturation of the DCs. The invention also relates to pharmaceutical compositions comprising said adapter protein and an adenovirus encoding an antigen and the uses thereof in a method for eliciting an immune response against the antigen encoded in said adenovirus as well as to antigen-loaded dendritic cells obtained the adaptor protein and an adenovirus and to the uses thereof in a method of eliciting an immune response against the antigen encoded in the adenovirus.Type: ApplicationFiled: May 19, 2009Publication date: March 31, 2011Applicants: PROYECTO DE BIOMEDICINA CIMA, S.L., THE UAB RESEARCH FOUNDATIONInventors: Alexander Pereboev, George Tsuladze, Igor Bogdashin, Itziar Echeverria Beistegui, Juan José Lasarte Sagastibelza, Jesùs Maria Prieto Valtueña, Pablo Sarobe Ugarriza
-
Publication number: 20100267623Abstract: The invention relates to peptides of general formula (I), wherein X is absent or X is present and is X14 or X14-X15, wherein X14 and X15, independently from one another, represent an amino acid; their functional variants and fragments, and their pharmaceutically acceptable salts, having the capacity to bind to scurfin and inhibit its biological activity, therefore they regulate or block the activity of regulatory T (Treg) lymphocytes. They are applicable in the treatment of infectious and neoplastic diseases.Type: ApplicationFiled: November 14, 2008Publication date: October 21, 2010Applicant: PROYECTO DE BIOMEDICINA CIMA, S.L.Inventors: Inés Noelia Casares Lagar, Francisco Borras Cuesta, Pablo Sarobe Ugarriza, Jesús Prieto Valtueña, Juan José Lasarte Sagastibelza
-
Publication number: 20100222280Abstract: The described peptides possess the capacity to bind to Transforming Growth Factor TGF-?1 (TGF-?1), and are potential inhibitors of the biological activity of TGF-?1 through direct binding to this cytokine. These peptides can be used in the treatment of diseases or pathological alterations based on excessive or deregulated TGF-?1 expression, e.g., liver fibrosis, pulmonary fibrosis, corneal fibrosis and haze.Type: ApplicationFiled: February 22, 2010Publication date: September 2, 2010Inventors: JAVIER DOTOR HERRERÍAS, ANA BELÉN LÓPEZ VÁZQUEZ, JUAN JOSÉ LASARTE SAGASTIBELZA, JESÚS PRIETO VALTUEÑA, FRANCISCO BORRÁS CUESTA, ESPERANZA FEIJOO BLANCO
-
Publication number: 20100168015Abstract: The invention relates to peptides having the capacity to bind to interleukin-10 (IL-10) and their use in the treatment of clinical conditions or pathological disorders associated to IL-10 expression, particularly to a high IL-10 expression, for example, infectious diseases, tumors, cancers and acute damage conditions.Type: ApplicationFiled: March 27, 2008Publication date: July 1, 2010Applicant: PROYECTO DE BIOMEDICINA CIMA, S.L.Inventors: Lorea Manterola Careaga, Inés Noelia Casares Lagar, Nancy Diaz-Valdés Farray, Javier Dotor De Las Herrerias, Juan José Lasarte Sagastibelza, Pablo Sarobe Ugarriza, Jesús Prieto Valtueña, Francisco Borràs Cuesta
-
Patent number: 7732397Abstract: Use of cardiotrophin in liver diseases. The invention describes the increased expression of cardiotrophin (CT-1) during the process of hepatic regeneration coinciding with maximum proliferation of hepatocytes and the role of CT-1 as a stimulator of hepatic regeneration. Furthermore, it describes the hepatoprotective role of CT-1 in various models of acute liver damage. The importance of using CT-1 in the manufacture of compositions for use in the treatment of hepatopathies is demonstrated. The invention describes such use in various forms and methods, including the recombinant protein and the use of the gene sequences that code for CT-1.Type: GrantFiled: March 11, 2004Date of Patent: June 8, 2010Assignee: Proyecto de Biomedicina Cima, S.L.Inventors: Matilde Bustos De Abajo, Jesús Prieto Valtueña, Juan José Lasarte Sagastibelza, Elena Baixeras Llano
-
Publication number: 20100047231Abstract: The present invention relates to an immuno-stimulant combination for prophylaxis and treatment of hepatitis C, characterised in that it comprises: a TLR3 agonist, a CD40 agonist and the NS3 protein of the hepatitis C virus. Moreover, the invention relates to the pharmaceutical compositions comprising said immuno-stimulant combination, to the use thereof, and to a kit composed of said pharmaceutical compositions. Finally, the present invention relates to a method for producing an immune response to the hepatitis C virus and to a vaccine against said virus.Type: ApplicationFiled: October 5, 2006Publication date: February 25, 2010Inventors: Aintzane Zabaleta Azpiroz, Francisco Borras Cuesta, Jesus Prieto Valtuena, Pablo Sarobe Ugarriza, Juan Jose Lasarte Sagastibelza
-
Patent number: 7666841Abstract: The described peptides possess the capacity to bind to Transforming Growth Factor TGF-?1 (TGF-?1), and are potential inhibitors of the biological activity of TGF-?1 through direct binding to this cytokine. These peptides can be used in the treatment of diseases or pathological alterations based on excessive or deregulated TGF-?1 expression.Type: GrantFiled: July 5, 2004Date of Patent: February 23, 2010Assignee: Proyecto de Biomedicina Cima, S.L.Inventors: Javier Dotor De Las Herrerías, Ana Belen Lopez Vazquez, Juan Jose Lasarte Sagastibelza, Jesus Prieto Valtuena, Francisco Borras Cuesta
-
Publication number: 20090263410Abstract: The present invention relates to the use of a peptide inhibiting TGF-?1 selected from: peptide p144 whose sequence corresponds to SEQ ID NO: 1, peptide p17 whose sequence corresponds to SEQ ID NO: 2, a peptide which has at least 90% homology therewith, or fragments of the above, in the preparation of an immune response modulating agent.Type: ApplicationFiled: October 24, 2005Publication date: October 22, 2009Applicant: Proyecto De Biomedicina Cima, S.L.Inventors: Francisco Borras Cuesta, Noelia Casares Agar, Javier Dotor De Las Herrerias, Lucia Gil Guerrero, Juan Jose Lasarte Sagastibelza, Pablo Sarobe Ugarriza, Jesus Prieto Valtuena